JP2023544406A - Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法 - Google Patents

Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法 Download PDF

Info

Publication number
JP2023544406A
JP2023544406A JP2023520432A JP2023520432A JP2023544406A JP 2023544406 A JP2023544406 A JP 2023544406A JP 2023520432 A JP2023520432 A JP 2023520432A JP 2023520432 A JP2023520432 A JP 2023520432A JP 2023544406 A JP2023544406 A JP 2023544406A
Authority
JP
Japan
Prior art keywords
subject
antigen
antibody
asthma
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544406A5 (enExample
Inventor
クリスティーン・シュー
ボランレ・アキンレード
ニキル・アミン
マルチェッラ・ラディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023544406A publication Critical patent/JP2023544406A/ja
Publication of JP2023544406A5 publication Critical patent/JP2023544406A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023520432A 2020-10-05 2021-10-04 Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法 Pending JP2023544406A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063087668P 2020-10-05 2020-10-05
US63/087,668 2020-10-05
US202063109719P 2020-11-04 2020-11-04
US63/109,719 2020-11-04
US202163144048P 2021-02-01 2021-02-01
US63/144,048 2021-02-01
US202163157922P 2021-03-08 2021-03-08
US63/157,922 2021-03-08
EP21315151 2021-08-31
EP21315151.7 2021-08-31
PCT/US2021/053328 WO2022076289A1 (en) 2020-10-05 2021-10-04 Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
JP2023544406A true JP2023544406A (ja) 2023-10-23
JP2023544406A5 JP2023544406A5 (enExample) 2024-10-11

Family

ID=78414079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520432A Pending JP2023544406A (ja) 2020-10-05 2021-10-04 Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法

Country Status (9)

Country Link
US (1) US20220169739A1 (enExample)
EP (1) EP4225436A1 (enExample)
JP (1) JP2023544406A (enExample)
KR (1) KR20230082650A (enExample)
AU (1) AU2021357078A1 (enExample)
BR (1) BR112023004020A2 (enExample)
CA (1) CA3194111A1 (enExample)
MX (1) MX2023003942A (enExample)
WO (1) WO2022076289A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
WO2024011251A1 (en) * 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
WO2025026821A1 (en) * 2023-07-28 2025-02-06 Novartis Ag New uses of omalizumab
TW202620051A (zh) * 2024-09-18 2026-05-16 香港商香港康乃德生物醫藥有限公司 介白素-4受體α抗體的使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507139A (ja) * 2014-02-21 2017-03-16 サノフィ・バイオテクノロジー Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
US11034768B2 (en) * 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507139A (ja) * 2014-02-21 2017-03-16 サノフィ・バイオテクノロジー Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Also Published As

Publication number Publication date
AU2021357078A9 (en) 2025-04-10
CA3194111A1 (en) 2022-04-14
MX2023003942A (es) 2023-06-02
US20220169739A1 (en) 2022-06-02
WO2022076289A1 (en) 2022-04-14
EP4225436A1 (en) 2023-08-16
KR20230082650A (ko) 2023-06-08
BR112023004020A2 (pt) 2023-04-25
AU2021357078A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP7636487B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
US20220169739A1 (en) Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
JP7592064B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
TW202106334A (zh) 藉由投予ｉｌ－３３拮抗劑治療或預防哮喘之方法
US20240360232A1 (en) Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
RU2855851C1 (ru) Способы лечения астмы у субъектов-детей путем введения антагониста il-4r
BR122026002779A2 (pt) Usos de um anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 para tratamento de asma, composição, medicamento, dispositivo tipo caneta de administração, autoinjetor para administração subcutânea, seringa e agulha padrão para administração subcutânea ou intravenosa, e kit
IL301777A (en) Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN116848138A (zh) 通过施用il-4r拮抗剂治疗儿科受试者的哮喘的方法
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
RU2832774C2 (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260630